Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3926-7267
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.39 billion
Profitability
Miscellaneous
Employees51,792
OptionableOptionable
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its quarterly earnings data on Thursday, November, 1st. The company reported $0.64 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.53 by $0.11. The company earned $4.53 billion during the quarter, compared to analysts' expectations of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm's revenue for the quarter was down 19.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.00 earnings per share. View Teva Pharmaceutical Industries' Earnings History.
When is Teva Pharmaceutical Industries' next earnings date?
How can I listen to Teva Pharmaceutical Industries' earnings call?
Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8669661396.
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?
Teva Pharmaceutical Industries issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $2.80-2.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.78. The company issued revenue guidance of $18.6-19.0 billion, compared to the consensus revenue estimate of $18.85 billion.Teva Pharmaceutical Industries also updated its FY 2018 guidance to $2.80-2.95 EPS.
What price target have analysts set for TEVA?
20 brokers have issued 1-year price targets for Teva Pharmaceutical Industries' stock. Their predictions range from $11.00 to $30.00. On average, they anticipate Teva Pharmaceutical Industries' share price to reach $22.4776 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.
What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 1 sell rating, 13 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.
What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
- 1. According to Zacks Investment Research, "Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business and a massive debt load. Nonetheless, Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and is reducing global workforce to revive growth. Teva expects to save almost $3 billion by the end of 2019 from these initiatives. Its financial position seems more stable than before as it is regularly paying down debt and there are signs of stabilization in U.S. generic drug pricing. Its newest drugs, Austedo and Ajovy, could emerge as significant contributors to long-term sales growth. Teva’s shares have outperformed the generic industry this year so far. " (12/3/2018)
- 2. Maxim Group analysts commented, "Teva reported 3Q18 with revenues of $4.53B vs. $4.55B consensus and beat on the bottom line with non-GAAP EPS of $0.68 vs. $0.55. The beat was driven by positive impacts from the ongoing restructuring strategy with a spend base reduction of $2B YTD compared to 2017 (excluding FX) and on track to reach $3B by YE19." (11/1/2018)
- 3. Cantor Fitzgerald analysts commented, "We rate TEVA 12-month price target of $25. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (9/27/2018)
- 4. Mizuho analysts commented, "We lowered 2018 estimates due to weaker but note that stronger Copaxone and EpiPen could make up the difference. We reiterate our Buy rating and $28 PT, but have become more cautious on a timely migraine approval on Sept 16. We see shares as undervalued even if approval is delayed." (8/24/2018)
Has Teva Pharmaceutical Industries been receiving favorable news coverage?
News stories about TEVA stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Are investors shorting Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 36,763,771 shares, a decline of 17.4% from the December 14th total of 44,517,110 shares. Based on an average daily trading volume, of 16,535,471 shares, the days-to-cover ratio is currently 2.2 days. Currently, 3.4% of the shares of the stock are short sold. View Teva Pharmaceutical Industries' Current Options Chain.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL) and Ono Pharmaceutical (OPHLF).
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
- Mr. Michael McClellan, Exec. VP & CFO (Age 48)
- Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
- Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
- Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)
Who are Teva Pharmaceutical Industries' major shareholders?
Teva Pharmaceutical Industries' stock is owned by a number of of retail and institutional investors. Top institutional investors include Nippon Life Global Investors Americas Inc. (0.06%), Cacti Asset Management LLC (0.06%), Greylin Investment Mangement Inc. (0.02%), Sterling Investment Management Inc. (0.01%), Virtu Financial LLC (0.01%) and DNB Asset Management AS (0.01%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Which institutional investors are selling Teva Pharmaceutical Industries stock?
TEVA stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Greylin Investment Mangement Inc., Sterling Investment Management Inc., Addison Capital Co, Macnealy Hoover Investment Management Inc. and Nisa Investment Advisors LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Which institutional investors are buying Teva Pharmaceutical Industries stock?
TEVA stock was bought by a variety of institutional investors in the last quarter, including Nippon Life Global Investors Americas Inc., Cacti Asset Management LLC, Fox Run Management L.L.C., Quadrant Capital Group LLC, Boston Advisors LLC and DNB Asset Management AS. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy shares of Teva Pharmaceutical Industries?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of TEVA stock can currently be purchased for approximately $18.82.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $19.08 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.
What is Teva Pharmaceutical Industries' official website?
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
